February Issue : 08 2023 An Insider Psychological Explana□on to Pain Management How to Overcome? Effec□ve Techniques Used to Manage Pain Artelo Biosciences Using Cu□ng-Edge Science with Lipid-Signaling Modula□on to Improve Trea□ng People with Cancer Most Promising PAIN in 2023 Management SOLUTION Providers Gregory D. Gorgas President, Chief Execu□ve Officer Artelo Biosciences Helping Technology Work With You & For You Editor’s Note ain management is an ever-evolving field, with new Ptreatments and technologies emerging all the time. As the healthcare industry shifts towards a more patient-centered approach, there is a growing need for pain management solutions that are safe, effective and tailored to individual patient needs. One of the emerging trends in pain management is the use of non-pharmacological interventions. With the growing concern over opioid addiction and abuse, non- pharmacological interventions like cognitive-behavioral therapy, acupuncture and physical therapy are becoming increasingly popular. These treatments are effective in managing pain and have fewer side effects than traditional pain medications. Another promising trend is the use of digital health tools to manage pain. The use of mobile apps and wearables to track pain symptoms and medication usage is on the rise. These tools provide patients with real-time data about their pain levels and can help healthcare providers make more informed decisions about treatment options. Personalized medicine is also playing an important role in the future of pain management. With advancements in genomics and molecular biology, healthcare providers can identify genetic variations that influence a patient's response to pain medications. This information can be used to develop personalized treatment plans that are more effective and have fewer side effects. Innovative medical devices and therapies are also transforming pain management. Devices like spinal cord stimulators and peripheral nerve stimulators can provide relief for chronic pain sufferers. Emerging therapies like stem cell treatments and regenerative medicine show great promise in repairing damaged tissue and reducing inflammation. Finally, there is a growing recognition of the importance of interdisciplinary care in pain management. A team-based approach that includes healthcare providers from different specialties, such as pain medicine, physical therapy and psychology, can provide patients with comprehensive care that addresses all aspects of their pain. In Insights Care's latest edition Most Promising Pain Management Solution Providers 2023, we bring to you a comprehensive list of companies that are leading the charge in providing innovative solutions to tackle pain management, a critical issue that affects millions of people worldwide. Hope you have an interesting read! -Pooja Shah The Future of Pain Management: Emerging Trends and Innova□ons Artelo Biosciences Using Cu□ng-Edge Science with Lipid-Signaling Modula□on to Improve Trea□ng People with Cancer 08 Ctts Cover Story t ts Effec□ve Techniques Used to Manage Pain How to Overcome? 32 Psychological Explana□on to Pain Management An Insider 20 Aicl Kipuwex Ltd. Revolu□onizing the Telehealth Industry with a Pa□ent-Centric Approach 16 Nen Evidence Based Solution S.L.U. (nen) A Pain Management Solu□on, Designed for Kids Figh□ng Cancer 24 28 36 Soovu Labs, Inc. Relieving Pain Through an Innova□ve Heat Delivery Approach Rescape Innovation Limited Reducing Pain and Anxiety Through Virtual Reality Editor-in-Chief Merry D'souza Senior Editor Anish Miller Managing Editor Pooja Shah Assisting Editors Saloni, Shreyasi Visualiser David King Art & Design Head Mrunalinee Deshmukh Co-designer Paul Belin Art & Picture Editor Sonia Raizada Business Development Manager Amy Jones Marketing Manager John Smith Business Development Executives Sarah Wilson, John Smith, Alex Vincent Sales Executives Kelli, Bill, Anna Technical Head Jacob Smile Assistant Technical Head Prachi Mokashi Technical Consultants David, Robert Digital Marketing Manager Alina Sege Assistant Digital Marketing Manager Renuka Kulkarni SME-SMO Executives Gemson Research Analyst Eric Smith Circulation Manager Tanaji Fartade Copyright © 2023 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success. Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Insights Care is powered by Insights Success Media and Technology Pvt. Ltd. February, 2023 sales@insightscare.com Contact Us: Follow us on : www.facebook.com/InsightsCare/ https://twitter.com/Insightscare Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - 302-319-9947 Email: info@insightscare.com For Subscription: www.insightscare.com Insights Success Media and Technology Pvt. Ltd. Survey No.133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027. Phone - India: 7410033802, 74100058552 Email: info@insightscare.com For Subscription: www.insightscare.com We are also available on : Most Promising Pain Management Solution Providers in 2023 Description Company Featuring Person Artelo Biosciences, Inc. Artelobio.com Gregory D. Gorgas CEO & President Artelo Biosciences, Inc. is a clinical stage company focused on modifying lipid-signaling pathways to improve treatments for people living with cancer. Bridges Paliative Care Bridgespalliativecare.com Erik Soiferman Owner Bridges Paliative Care’s goal is to help you achieve the best possible outcome and overall quality of life throughout your illness. DORN Dorncompanies.com Kevin Lombardo President CEO DORN is a disruptive innovator and the country’s leading wellness-based pain management and injury prevention company, committed to reducing costs of healthcare, workers’ compensation and lost productivity. KIPUWEX OY LTD Kipuwex.com Marko Höynälä CEO & Founder KIPUWEX OY LTD is a small wireless IoT device that continuously measures different physiological parameters from the patient digitally, converting them with an algorithm into pain data and provides efficiently reliable measurements for healthcare professionals and home users. Francesca Wuttke / Xenia Riasol Founder & CEO / COO Nen provides evidence based health designed for children’s minds to improve their lives. Alan Doucet Executive Director Plymouth Bay Orthopedic Associates, Inc. goal is to help patients live a more active and rewarding life. Matt Wordley CEO Rescape California is a non-profit organization that educates about and advocates for a whole-systems approach to landscaping that works in harmony with the natural world and addresses the changing environment. Soovu Labs, Inc Soovu.com Allan Stephan Co-founder and CEO Soovu Labs, Inc helps individuals overcome pain and get back to their lives and work. Nen Nen.health Plymouth Bay Orthopedic Associates, Inc. Pbortho.com Rescape Rescape.health Gregory D. Gorgas President, Chief Execu□ve Officer Artelo Biosciences Cover STORY cross the healthcare community, a serious Achallenge while delivering care is assisting patients with both acute and chronic pain management. Particularly so for people living with cancer. The initial stage of treating any disease or ailment is diagnosing the cause and treating it with appropriate interventions, including drugs or varied therapeutic approaches as required. However, a standard diagnosis- treatment-healing paradigm doesn’t always work well for a person living with cancer. Through the cancer treatment journey, a person diagnosed with cancer may encounter considerable peripheral pain (neuropathy), bone inflammation, gastrointestinal infection, low musculoskeletal functionality, or other complications. A 2020 public health research indicates that around 20% to 50% of cancer survivors experience pain. Yet, 30% of those who do not receive relief from their pain experience a negative impact on their quality of life. As cancer advances, pain can intensify by up to 80%, severely impacting a person’s quality of life. These statistics motivate the research community to discover new and robust solutions. One potential alternative emerging from clinical research on cancer pain has spotlighted the role of the body’s own Endocannabinoid System (ECS). This cell-signaling network is one of the largest in the body and is associated with regulating pain sensation. At Artelo Biosciences—a clinical-stage company using cutting-edge science to improve patient care, drug development based upon targeting the ECS is showing Artelo’s drug candidate, ART26.12 has the poten□al to stand out in the market due to its poten□al therapeu□c value in preven□ng and trea□ng chemotherapy-induced peripheral neuropathy (CIPN), a common and o□en painfully debilita□ng complica□on of cancer therapies. Most Promising Pain Management Solu□on Providers in 2023 Using Cu□ng-Edge Science with Lipid-Signaling Modula□on to Improve Trea□ng People with Cancer promise. The company applies leading-edge scientific, regulatory and commercial disciplines to develop innovative therapies, with a particular focus on the needs of the cancer patient. Realizing the merit of targeting the ECS, Artelo is on a mission to alter the course of treatment for those diagnosed with cancer and other serious conditions. Spearheading Artelo with innovation, conviction and leadership is the company’s President and Chief Executive Officer—Gregory D. Gorgas. Committed to improving the lives of the millions of patients worldwide with cancer diagnosis, he recruited a team of like-minded researchers, clinical professionals and business executives in San Diego and abroad to create Artelo. Acknowledging such progress at Artelo, we crossed paths with Gregory Gorgas to learn more about the company and its mission to meaningfully impact cancer care. Let’s dive in to know more! Artelo Biosciences—At a Glance! Artelo is a story of empathy, innovation and scientific revolution. Being enriched with the vision and operational experience of its CEO—Gregory Gorgas, the company aims to transform the care of a large number of people suffering through multiple diseases and conditions, including cancer, pain, anorexia, anxiety, neuropathy, and inflammation with the help of its novel product candidates in development designated as ART27.13, ART26.12, ART12.11. Aware of the tremendous promise of targeting the ECS with lipid- modifying drugs to treat cancer, pain and central nervous system (CNS)-related conditions, Artelo initiated its quest for innovative research early in 2017. By the end of that year, the company had acquired rights to multiple technologies and filed a patent on its own invention. In sum, Artelo’s portfolio represents the broadest spectrum in the pharmaceutical industry of methods targeting the ECS for the improvement of health. In early 2023, Artelo expects to start enrolling patients in the Phase 2 stage of the Cancer Appetite Recovery Study (CAReS) with its lead clinical program, ART27.13. Cancer anorexia (loss of appetite or aversion to food) affects over 60% of people with a cancer diagnosis and is a leading cause of death for cancer patients. ART27.13 was designed to arrest the anorexia and resulting weight loss experienced by the majority of cancer patients. Like the other programs at Artelo, ART27.13 targets the receptors of the ECS. It leverages a known effect on hunger without the undesired CNS effects of cannabis. And the company is well-funded to complete the CAReS trial as its last reported cash was nearly $20 million. Another complication of cancer is pain secondary to the toxic effects of certain cancer chemotherapies. A key initiative of Artelo is to bring its second drug candidate into the clinic within the next 18 months. In multiple preclinical animal studies, ART26.12 has shown remarkable promise in treating painful neuropathies associated with chemotherapy. Artelo’s researchers showed that ART26.12 was able to not only successfully treat the pain, but also prevent the neuropathic pain from even starting. Currently, there are no FDA-approved treatments for chemotherapy-induced peripheral neuropathy (CIPN). Artelo is on a mission to change that. Transforming Pain Management ART26.12 is a new chemical entity. Because ART26.12 is at the forefront of Artelo’s innovation, we asked Mr. Gorgas to elaborate on the science and strategy with this novel compound. He explained that ART26.12 is a selective fatty acid binding protein 5 (FABP5) inhibitor. It inhibits a pathway that can raise endogenous levels of endocannabinoids, the body’s self-made cannabinoids. ART26.12 has the potential to stand out as a treatment due to its therapeutic value in preventing and treating CIPN, a common and often painfully debilitating complication of cancer therapies that often results in a reduction or interruption of cancer treatment. CIPN is frequently so painful that patients cannot progress on their anti-cancer therapy. In preclinical models, inhibition of FABP5 using ART26.12 has shown activity in analgesia, reversing the effects of CIPN, a condition for which there are currently no approved treatments. Current pain management medications typically have significant side effects and/or addictive properties. To date, FABP5 inhibition has shown little to none of these effects while exhibiting good analgesic properties. In addition to pain, inhibiting FABP5 may be useful in other areas of unmet need. Of recent note, landmark research in anxiety with another one of Artelo’s FABP5 inhibitors was selected as one of the top 50 (out of 12,000 research studies submitted) at the Society of Neuroscience annual meeting in November 2022. The preclinical results indicated that a novel FABP5 inhibitor from Artelo’s extensive library of FABP inhibitors significantly reduced anxiety behaviors without the abuse potential or cognition blunting of other treatments for anxiety disorders. There, it was concluded that modulation of the FABP5 system might serve as a promising target for the development of novel anxiolytics. Key Development Programs Artelo’s full-spectrum approach to modulating the ECS with lipid-modifying approaches include:. Ÿ ART27.13, a cannabinoid (CB and CB ) receptor 1 2 agonist, being investigated in the CAReS trial, currently enrolling patients with cancer anorexia. Ÿ ART26.12, a fatty acid binding protein 5 inhibitor, with regulatory-enabling studies well underway aiming to have the program in the clinic for chemotherapy induced peripheral neuropathy within 18 months. A first for a FABP5 inhibitor. Ÿ ART12.11, a patented cocrystal composition of cannabidiol (CBD), in preclinical development for anxiety-related disorders including post-traumatic syndrome disorder (PTSD), as well as other potential indications. If approved by the FDA, ART27.13 in cancer anorexia and ART26.12 in chemotherapy- induced peripheral neuropathy would be first-in-class treatments for people that have no currently approved treatment op□ons. If approved by the FDA, ART27.13 in cancer anorexia and ART26.12 in chemotherapy-induced peripheral neuropathy would be first-in-class treatments for people that have no currently approved treatment options. Artelo also believes its CBD cocrystal has the potential to be a best-in-class drug. Wholistic Thinking-Treating the Whole Person While several of Artelo’s programs may ultimately be useful as anti-cancer agents directly, Mr. Gorgas says the mission of Artelo today is to treat the whole person with cancer. While there have been many advancements in the treatment of tumors over the past two decades, cancer pain and cancer anorexia are still without FDA-approved treatments. Mr. Gorgas lamented that treatment of cancer anorexia has not advanced since he started his career in the pharmaceutical industry nearly 40 years ago, and the team at Artelo aims to change that. Using a mechanism-based approach modulating the ECS holds therapeutic promise that may have eluded research to date. Artelo’s priorties for 2023 are 1.) the rapid accrual in the CAReS Phase 2 with an expansion of clinical sites in United Kingdom and Europe, 2.) gaining alignment with the FDA on the pathway and research to bring ART26.12 Current pain management medica□ons typically have significant side effects and/or addic□ve proper□es. But to-date, Artelo’s FABP inhibi□on has shown li□le-to-none of these effects while exhibi□ng good analgesic proper□es. into the clinic for CIPN (a first for a FABP5 inhibitor), and 3.) advance and expand the understaning of differentiating properties of its patented CBD cocrystal. Transformative Leadership—The Intersection of Experience and Innovation Mr. Gorgas brings almost four decades experience to his role in leading Artelo. Before founding Artelo, he served as Senior Vice President, Commercial and Corporate Officer at Mast Therapeutics, a publicly-held biotechnology company. There, he had commercial leadership accountability and business development responsibilities for the hematology, oncology and cardiovascular franchises. Prior to that, he worked at Biogen, a publicly-held biotechnology company, as Senior Director, Global Marketing, with responsibility for the strategic vision and operational commercialization of the company’s worldwide cancer business. Furthering his commitment to bring healing to people living with cancer through innovative therapeutics, Mr. Gorgas became convinced that targeting the body’s endocannabinoid system with lipid-signaling drugs could lead to new solutions to old problems. This led Mr. Gorgas to establish Artleo Biosciences. Modulating the ECS with federally-compliant cannabinoid-based drug research has some added complexity and challenges, but the transformative potential of the programs at Artelo makes it worth the effort. And Artelo has a competitive advantage of having successfully navigated complex regulations to advance its programs across the globe. Mr. Gorgas envisions benefiting millions of patients worldwide through the product development at Artelo Biosciences. The company seeks to attain this vision through the application of innovative, next-generation science to real-world challenges for people living with cancer. Currently, alongside the business potential, Mr. Gorgas and the team at Artelo derive their motivation to solve pharmaceutical challenges that have eluded the industry for decades. Words of Wisdom Years ago, Mr. Gorgas read Peter Medawar’s “Advice to a Young Scientist,” who wrote, “In choosing topics for research...to enlist in, a young scientist must beware of following fashion.” Mr. Gorgas found it to be an essential suggestion. Following fashion in science or on Wall Street often leads to dead ends. “When we started Artelo in 2017, federally- compliant research into the endocannabinoid system was very new and few dared to pursue the path, but that didn’t dissuade us. We were convinced that lipid-modulating drugs would ultimately prove their value in treating serious medical conditions like cancer pain and anorexia,” says Mr. Gorgas. “Decades of commitment and smart science pursued by pioneer researchers in the ECS like Artelo’s Chief Scientific Officer, Andy Yates, Ph.D., and Professor Saoirse O’Sullivan, Ph.D., now Artelo’s Vice President of Translational Research are beginning to pay dividends. We are excited to be a leading company with this innovation, and through our efforts we hope people with cancer will live better in the decades to come than in decades past.” Artelo Biosciences is traded on the Nasdaq Capital Markets exchange (Nasdaq: ARTL) and has analyst coverage with Ladenburg Thalmann & Co. Inc., H.C. Wainwright & Co., and Maxim Group. Stay in touch. Subscribe to Insightscare Get Insightssuccess Magazine in print, & digital on www.insightscare.com Never Miss An Issue Subscribe Today Corporate Office Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin,OH 43017, United States Phone - (614)-602 - 1754,(302)-319-9947 Email: info@insightscare.com For Subscription : www.insightscare.com Check should be drawn in favor of : INSIGHTS SUCCESS MEDIA TECH LLC www.insightscare.com Marko Höynälä CEO and Founder Kipuwex Kipuwex Ltd. Revolutionizing the Telehealth Industry with a Patient-Centric Approach Patients who face communication adversities, such as young children, people with mental illnesses, and critically ill patients, have difficulty being assessed for pain. Premature infants whose central nervous systems have not yet formed and may experience disastrous effects require specific attention when it comes to pain treatment. Marko Höynälä is the CEO and Founder of Kipuwex, a company that develops a small wireless IoT device that continuously records a patient's physiological parameters digitally, converts those parameters into pain data using an algorithm, and provides accurate measurements for both healthcare professionals and at-home users. Marko is a globally well-known inventor from Oulu, Finland, with global experience in multiple technology fronts, including the IoT (Internet of Things), IoMT (Internet of Medical Things), AI (Artificial Intelligence), Remote Patient Monitoring (RPM), and telehealth industries. Here are the interview specifics that shed light on the pressing need to address chronic pain assessment and how Marko Höynälä is overcoming this obstacle with Kipuwex. Kindly brief us about Kipuwex and its inception story. Chronic pain is a deeply personal issue to me, as my father suffered from cancer. I saw how destructive chronic pain can be. He couldn’t handle the pain and committed suicide. Chronic pain is one of the largest medical burdens worldwide; we can’t even measure it consistently, so how can we treat it properly? Pain is often underdiagnosed or overtreated, both of which have long-term impacts on the lives of those it affects. It was the year 2015 when I came across the local Northern Ostrobothnia Hospital District’s innovation competition, in which four major global problems were faced by healthcare professionals. One of the difficulties was objectively measuring the children's pain. I won the competition, and that was the start of the Kipuwex company. It was highly important that winning the hospital district’s innovation competition meant getting to work closely with healthcare professionals. Today, we have extended our collaborations with leading medical institutions and hospitals within Europe and Asia. At first, we started to develop an automatic and objective medical device for pain measurement, but during the journey, we changed our strategy. Kipuwex device will be launched in the healthcare market as a comprehensive remote monitoring device. In the second phase, we will integrate a pain measurement feature. What are the core values of Kipuwex, and how are you driving Kipuwex to achieve its mission and vision statement? I have over 20 years of experience in software development, so it has been very logical that our core competencies are software, developing cloud services, algorithms, applications, and all the other IoT (Internet of Things) and IoMT (Internet of Medical Things) technologies. With Kipuwex, we want to tackle three major healthcare problems. rising costs of healthcare, e.g., in the USA, 20% of GDP goes to healthcare. There's a lack of access to affordable healthcare; at least half of the world’s 8 billion people still do not have access to essential health services. Chronic pain is a major global issue, affecting 20% of Most Promising Pain Management Solu□on Providers in 2023 February 2023 17|www.insightscare.com adults worldwide and costing $560-635 billion in the United States alone each year. "Kipuwex’s mission is to combat healthcare inequality and help millions of people." "Kipuwex’s vision is to become a world-leading company in the pain management domain." Enlighten our readers about the key products and offerings of Kipuwex and highlight any service that is its USP. Kipuwex is a small, wireless IoMT device that measures 12 different physiological parameters, including pain. The device is attached to the patient’s chest with a disposable ECG sticker. We measure more physiological parameters than any other similar device on the market. We have developed Kipuwex so that it is affordable for developing countries as well. Currently, we are developing for home users the first complete health report in the world. It's a consumer-centric digital health ecosystem for remote patient monitoring in cooperation with a unique global partnership. Also, there are well-being algorithms for preventive care and personalized heart and emotional well-being monitoring. In your opinion, what are the current challenges in the pain management industry? How are you infusing your leadership skills and expertise over the years to create a flourishing industry with opportunities and growth? The medical device business is very challenging. It’s a very long process to develop a new medical device and to launch it. The road to a successful launch can be filled with product development risks. Of course, it involves numerous legal and economic considerations, so we need to think and Kipuwex’s advantage and competitiveness are based on the fact that the company has integrated so many sensors into such a small IoMT device. February 2023 18|www.insightscare.com apply. Companies must comply with regulations, which can be time- and money-consuming. The biggest challenge is how to make funding last through product development and to get sufficient funding to finalize the product development. The global pandemic was a huge challenge and postponed clinical trials. Product testing should begin early in the development process and continue throughout. The war in Ukraine has caused a lack of components. The present research is serving as the baseline for better future strategies to improve global health initiatives, as our ecosystem is very scalable and can be integrated as well. We are getting continuous questions, is it possible for third parties to integrate our platform in their own use cases? Opportunities are quite endless when thinking of growth potential. What are the latest technological advancements adopted by Kipuwex to deliver the best pain management services in the industry? How is it impacting the demographic concerned? Kipuwex product is protected by patents and know-how. Our advantage and competitiveness are based on the fact that we have integrated so many sensors into such a small IoMT device. For the pain measurement feature, we are granted two patents, which are essential and extremely important to stimulate the innovation, development and commercialization of Kipuwex. As an experienced leader, what would be your advice for aspiring entrepreneurs and enthusiasts who wish to venture into the MedTech sector? Being an entrepreneur is difficult, especially in the MedTech industry, which is difficult in many ways. It also needs years of hard work to go to market. You must have a strong vision, mission and problem-solving abilities that are more than just business to you. What are the future goals of Kipuwex, and How do you envision scaling up its operations and reach in 2023 and beyond? Kipuwex's mission is to provide remote monitoring devices throughout the world. Our vision is to become a world- leading company in the pain management domain. The Words that Signify a Bequest “Billions of people still do not have access to essential health services, and at the same time, health care costs are unsustainable across the world. Next generation sensor technologies, in combination with smart algorithms, bring unlimited opportunities to ensure accessible and affordable healthcare solutions. Kipuwex remote monitoring device is well positioned to play an important role in revolutionizing the integration of quality healthcare outside hospitals.” Ÿ Prof. Dr. Niclas Adler, CEO and Founder of Adler Industries. CEO and Founder of Synthesis Group, iHealth Solutions, and iPower Group. Stockholm, Sweden “Kipuwex is one of the state-of-the-art devices for pain management, which is the need of the hour in this era of digitalization and can revolutionize pain management in certain sectors of the population. It also has the promise of being utilized as a unique remote vital parameter monitoring device such as in emergency kits, and such devices have now become a necessity.” Ÿ Prof. Dr. MCh. B J Rajes, Consultant Neurosurgeon at Yashoda Hospitals, Hyderabad, Telangana, India February 2023 19|www.insightscare.com Management Explanation to ince pain is a subjective experience, each person Sexperiences it differently. Physical or psychological pain can affect a person's mental and emotional well- being. Torment the board includes various strategies and techniques to assist people with dealing with their aggravation. Psychological explanations for pain management can also be beneficial, in addition to physical treatments like therapy and medication. Let's examine the psychological basis for pain management and its benefits! Understanding the Psychological Basis for Pain Management Psychological pain management entails the application of a variety of strategies to assist individuals in coping with pain. According to the psychological explanation of pain management, pain is both a physical and a psychological experience. This indicates that a person's thoughts, feelings and actions can impact pain. According to the psychological explanation of pain management, these psychological factors can be addressed to manage pain. For instance, a person's perception of pain can be influenced by their beliefs. A person's pain may become more severe if they believe it is intolerable and unmanageable. However, people may feel more in control of their pain if they think it can be managed. Reconceptualizing Pain Fear of pain is normal because it is a natural learning tool and a horrible feeling. Patients who experience persistent pain tend to develop a fear of pain and, as a result, stop doing activities that make them feel pain, such as moving their bodies, which is typical of osteoarthritis. Through education, rethinking pain, cognitive behavioral therapy (CBT), and the other methods on this page, the cycle of chronic pain and disability can be broken. This fear of pain can become a cycle that never ends. February 2023 20|www.insightscare.com Cognitive Behavioural Therapy (CBT) One approach for psychological pain management is cognitive behavioral therapy (CBT). The goal of cognitive behavioral therapy is to assist people in recognizing and altering negative thoughts and actions that cause pain. CBT, for instance, can help people challenge the belief that they are weak or damaged due to pain and develop more positive and realistic views. Mindfulness Care is one more method utilized in the mental torment of the board. Being aware of the present moment and accepting it without judging it is mindfulness. Stress and anxiety can be reduced through mindfulness, which can assist individuals in pain management. Stress and nervousness can exacerbate the aggravation, so diminishing these feelings can assist with overseeing torment. Massage Massage treatment, like unwinding, is commonly utilized as an assistant to conventional treatment modalities. It is generally used close by and contrasted with unwinding and other mental medicines, so remembering was considered advantageous. Since its inception in the 2nd century BC, massage therapy has developed numerous techniques and subfields, including Swedish massage, Shiatsu, Rolfing, reflexology, and craniosacral therapy. In one of the studies, massage was more effective than a placebo treatment. In the remaining seven studies, there was no significant difference between exercises and corsets, and the massage was superior to relaxation, acupuncture and education. Relaxation Therapy Relaxation can take a variety of forms, including spiritual or non-spiritual meditation, progressive relaxation or muscular contraction and relaxation, and even imagery. It is generally used in conjunction with other treatment modalities. Typically, relaxation is considered an "Alternative" treatment that must be used in conjunction with conventional medical care rather than on its own. This could be because the treatment's theoretical foundations haven't been proven or there isn't enough high-quality evidence to support it. Restoring normal equilibrium within the body's systems is one way that relaxation therapy may be effective. This can be accomplished by reducing the effects of stress on the body. The body's most fundamental response to stress is a "fight or flight" response that triggers several biochemical changes. Benefits of Psychological Explanation to Pain Management The psychological explanation for pain management has numerous advantages over spinal manipulation and transcutaneous electrical nerve stimulation in terms of effectiveness. First, it can give people a sense of control over their pain. People may feel more empowered to manage their pain when they realize their thoughts and actions can affect it. Self-confidence and self-esteem may rise as a result. Second, these methods may lessen the requirement for medication. Medication can potentially alleviate pain, but it can also have adverse effects and become addictive. Psychological techniques can be used to manage pain independently or with medication. Thirdly, psychological pain management has the potential to enhance a person's quality of life. Torment can essentially affect an individual's psychological and profound prosperity. People can improve their mood, reduce stress and anxiety, and participate in more social activities by controlling pain. In sum-up, The psychological explanation of pain management suggests that pain is a psychological and a physical experience. People can better manage their pain by addressing the psychological factors that cause it. Psychological methods for managing pain, such as cognitive behavioral therapy (CBT) and mindfulness, can give people a sense of control over their pain, lessen the need for medication, and raise their overall quality of life. Talking to a medical professional about psychological pain management methods might be helpful if you are having pain. - Shreyasi Shelke February 2023 22|www.insightscare.com Nen Evidence Based Solution S.L.U. (nen) A Pain Management Solu□on, Designed for Kids Figh□ng Cancer ediatric cancer is a global problem that children and Ptheir families struggle with. Almost 500,00 children will be diagnosed with cancer this year and nearly all of the will experience pain during their first year. Pain management in children remains an enormous unmet medical need that is not currently served by current practices. Because of the relative homogeneity of pain in cancer (procedural pain and pain from cancer itself), Nen Evidence-Based Solution S.L.U. (nen), a clinical-stage company is developing evidence-based digital therapeutics to help kids fighting cancer, their families and their doctors manage pain. Pain management is addressed through play, by leveraging gamification of cognitive behavioral therapy to modulate pain and improve a child's overall well-being and outcomes. Through validated outcome measures, both families and physicians can provide insightful and tailored pain management support to children who currently lack alternative means to express their needs. With the support of Francesca Domenech Wuttke (Founder & CEO) and Xènia Riasol Cercos (COO), nen is a mission-driven profit-for-purpose company to democratize pain management at scale to all kids who are in pain, wherever they are. Let's dive in to learn about Nen's operations in meeting its objective. What inspired you to establish Nen Health? When I started thinking about my next steps, I wanted to do something with a more direct patient impact. I put my consulting hat back on and did a scan of the whole of the digital health market to identify gaps. I wanted to know what those gaps are and if can they be filled with a digital solution or service but more specifically with a digital therapeutic. I feel strongly that DTx is the fourth wave of medicine: small molecules, biologics, cell and gene therapy, and now digital therapeutics. I was surprised by the dearth of activity in the pediatric digital health space and had worked on a DTx for pain in adults and saw how readily the CBT modules could be translated to a digital platform and thought why not apply that to kids that were the genesis of nen. What are the core values of the company? How are you driving the company to achieve its mission and vision statement? nen is focused on developing kid-centric care designed for their minds- because kids matter and we are committed to kids. nen offers a novel mission-driven approach to address pain management through play leveraging gamifica□on approaches and cogni□ve behavioral therapy (CBT) to modulate pain and improve their overall well-being and outcomes. We are crea□ng an app-based pla□orm for smartphones/tablets. The CBT modules will be age- appropriate and designed for children to be engaging and enjoyable for them. Most Promising Pain Management Solu□on Providers in 2023 February 2023 24|www.insightscare.com Francesca Wu□ke is the CEO and Founder of nen-bringing evidence- based Digital Therapeu□cs (DTx)pain solu□ons to kids with cancer. Dr. Wu□ke brings broad drug development and healthcare exper□se in both the US and Europe, with nearly 30 years of clinical, commercial, strategic and transac□onal experience. She has worked with diverse organiza□ons including start-ups, consul□ng, large and specialty pharma as well as academia. Formerly, she was the Chief Digital Officer of Almirall where she created the Almirall Digital Garden to accelerate and incubate digital health startups. Dr. Wu□ke worked at Novar□s where she was responsible for two Cell and Gene therapy opportuni□es that were successfully brought into the organiza□on as well as managing the strategy and commercializa□on for the exis□ng por□olio of cell therapy assets. Dr. Wu□ke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences. About the Founder Francesca Domenech Wu□ke Founder & CEO Nen Evidence Based Solu□ons, S.L.U. (nen) February 2023 25|www.insightscare.com About the COO Xènia Riasol is the Chief Opera□ng Officer of nen. She is experienced in launching digital therapeu□cs across Europe and in crea□ng and deploying customer-centric digital solu□ons globally. Xenia is a digital innova□on and strategy expert with a focus on commercializa□on models and global solu□on deployment. She has extensive experience in Pharma, where she was bringing digital innova□ve solu□ons to pa□ents and managing strategic digital marke□ng campaigns globally. As Chief Opera□ng Officer, Xenia is responsible for leading the product planning and evolu□on, marke□ng strategies, and for the everyday running of the business, turning industry knowledge into ac□onable business channels and revenue streams for the company. She works with investors, partners, advisors and pa□ents to manage the strategy and path forward for nen. Xènia Riasol Cercos COO Nen Evidence Based Solu□ons, S.L.U. (nen) February 2023 26|www.insightscare.com How big is the addressable market? Pain management in children remains an enormous unmet medical need that is not currently served by current practices. To date, no current solutions exist to moderate pain designed specifically for kids. The current modalities including pain assessment and then treatment scales are incredibly subjective and not appropriately modified for use in children, particularly in small children. nen offers a novel mission-driven approach to address pain management through play leveraging gamification approaches and cognitive behavioral therapy (CBT) to modulate pain and improve their overall well-being and outcomes. We are creating an app-based platform for smartphones/tablets. The CBT modules will be age- appropriate and designed for children to be engaging and enjoyable for them. Who are your target customers? nen's first indication is for school-aged children from 7-12 years old, as they have more developed neurodevelopmental skills where CBT is considered a clinically validated and well-established therapy. After we have established a solid and tested the regular nen solution (with proven efficacy and learnings) nen will continue to develop the platform to serve patients from 2-6 as this age group remains a huge unmet need as very few digital solutions for pain management are addressed specifically to them and yet they too suffer from pain (both physically and psychologically). We will then expand to adolescents. As an experienced leader, what advice would you like to give to aspiring entrepreneurs and enthusiasts who wish to venture into the competitive industry that you are serving? Patience and resilience. There will be a lot of no's along your path but if you stay true to your mission and vision you can achieve great things. What are the future goals of the company? How does it envision scaling up its operations and reach in 2023 and beyond? We have designed our business model with flex so that we are not reliant on the ever-changing regulatory landscape. Ÿ B2C: The first iteration is a pediatric oncology patient support tool, designed for GDPR/HIPAA and ISO compliance at inception and with parallel development in US and Europe in English (UK and American) Spanish, French, Italian, German, and Dutch. This tool will initially be targeted to parents so we can beta-test the outcomes. We expect to launch this product in late 2023 and then after it is clinically validated, we will offer a premium product (identical to the PDT) with robust medical claims at a higher price point. Ÿ B2B: Next, we will continue to forge research collaborations with academic institutions to generate clinical evidence while gaining champions. Ÿ Rx: Standalone Prescription Digital Therapeutic (PDT.) Once registered as SaMD, or under DiGA or similar laws, we will seek reimbursement as a standalone PDT across various payor systems, models and geographies. February 2023 27|www.insightscare.com Rescape Innovation Limited Reducing Pain and Anxiety Through Virtual Reality n several healthcare specialisms, doctors and Icaregivers are often puzzled about the best way to help their patients cope with pain and anxiety, two dominant concerns of their suffering. This is because patients during treatments are usually focused on their pain, which increases their perception of pain. Not only do they feel anxious about it, but they also end up feeling helpless and out of control over the situation. In response to such a pain dilemma, distraction has proven to be an effective coping tool to help patients reduce their pain and anxiety. It encourages them to focus on a specific task (i.e., a pleasurable activity, puzzles, games, etc.) and attain a sense of control. With the proven effectiveness of distraction as a tool, Rescape Innovation Limited provides a unique solution to ease the lives of patients. Its Class-one innovative medical device, DR.VR™, enables quick, easy and monitorable deployment of virtual reality therapy to improve the patients' reported level of pain and has been effective compared to opioid analgesics. In an interview with Insights Care, Matt Wordley, the CEO, talks about the role of virtual reality in clinical practice, along with Rescape's contribution in delivering it to improve the experience of patients' pain and anxiety. Below are the highlights of the interview. Kindly brief us about the company and its inception story. Rescape Innovation was born when I attended a TED talk by a palliative care consultant, Professor Mark Taubert, who explained the difficulties of communicating with his patient cohort. There I developed an interest in immersive technology through other business interests and felt that I would be able to use the technology to address some of the issues that had been raised in the TED talk. I spoke to Professor Taubert immediately after the talk and the journey of Rescape began! Please tell us about yourself and your professional journey so far. I am one of the original creators of The Orchard Media Events Group. I have been instrumental in building it into a world-class agency, TV production company and Live Music promoter. As an earlier adopter and advocator of VR technology within Orchard, Rescape was spun out to unlock the healthcare opportunity, and I took the reigns as CEO. What are the core values of the company? How are you driving the company to achieve its mission and vision statement? Very early on we saw the impact that Virtual Reality Therapies could have on patients' pain and anxiety. This was anecdotal but very clear and we started to evidence this impact. We committed then to helping as many patients as possible have access to VR treatments. This core value is an important principle we try to benchmark everything we do against. VR should be available to all and we're determined to deliver against this promise. Could you please list the key products and offerings of the company? Also, please put light on any service that is the company's USP. DR.VR is a Class 1 medical device that is being utilized by hospitals, care homes and hospices to alleviate anxiety and reduce the perception of pain for patients and family members of patients. Another product is Frontline, which has been designed to support the well-being of NHS staff and has also been adopted by several universities to support staff and students. February 2023 28|www.insightscare.com The priority for our development team is on ensuring that user-centric design is at the heart of all we do as that gives us the ability to deploy simple solutions at scale, ensuring that the benefits of immersive therapeutics are enjoyed by as wide an audience as possible. In your opinion, what are the current challenges in the pain management industry? How are you infusing your leadership skills and expertise over the years to create a flourishing industry with opportunities and growth? We are at the beginning of a fundamental shift in medicine adopting a more holistic view of the patient. Historically mental and physical health have been treated independently as if they were unconnected and this divide is very slowly being bridged. Pain is a complex, multifaceted biopsychosocial problem that requires a solution that addresses multiple elements concurrently and chronic pain clinics are now starting to use a multidisciplinary approach to treatment involving psychiatrists, psychologists, anesthetists, physiotherapists, nurses and occasionally social workers. Our job is to build the evidence base to prove that Immersive Therapeutics should be an important component in treating pain by addressing mental and physical health at the same time and become a mainstay in the suite of treatment options to help patients. What are the latest technological advancements adopted by your company to deliver the best pain management services in the industry? How is it impacting the demographic concerned? We call ourselves pragmatic technologists; the real world is never easy and always messy. We are proud that our DR.VR solution is user-friendly for both patients and clinicians. We have a phrase we use when developing content "Don't create things to watch but space to inhabit." This is a key remit for successful VR pain therapies; the deeper level of immersion we create, the more success we can create. As an experienced leader, what advice would you like to give to aspiring entrepreneurs and enthusiasts who wish to venture into the competitive industry that you are serving? Understand the complete system you are trying to work within. Sadly it's not good enough to just create a Virtually Reality that has therapeutic benefits. You have to deliver a simple and deployable solution. Read up, research and Very early on we saw the impact that Virtual Reality Therapies could have on patients' pain and anxiety. This was anecdotal but very clear and we started to evidence this impact. Based on the Virtual Reality principle, our innovative product, DR.VR, is a Class 1 medical device that is being utilized by hospitals, care homes and hospices to alleviate anxiety and reduce the perception of pain for patients and family members of patients. Matt Wordley CEO Rescape innovation Limited Most Promising Pain Management Solu□on Providers in 2023 February 2023 29|www.insightscare.com embrace user-centric design practice and you will develop much better solutions. At times that means embracing the elephant in the room and tackling the hard things head-on. There are so many examples where we have done this from a lack of NHS wifi to infection control protocols or making sure our content reduces motion sickness. What are the future goals of the company? How does it envision scaling up its operations and reach in 2022 and beyond? The opportunities for the use of VR in healthcare are in their infancy. We have several exciting research projects that will be concluding in 2023 and we're excited about the opportunities this will open. Referencing our core values, we want to give access to as many people as possible and in '23 we will be launching a pain solution that can be accessed from home. This in part, is driven by a growing number of patients that have asked if they can use the solution at home. Give us a few testimonials from your clients or customers and awards or recognition that accurately highlight your company's position in the market. "VR intervention demonstrated a significant reduction in patient and parental anxiety both pre-operatively and in the fracture clinic." "The improvement in patients' reported pain after VR, particularly for those patients with higher pain scores (3.41 points out of 10), was remarkable and is comparable with opioid analgesics." Dr. Ceri Lynch, published in ICU Management. “91% [of patients] reported lower anxiety levels after using the headset." Potter, T., Curran, Jr, 2021 Using DR.VR® in a Burns Unit "I have been a nurse for over 25 years, working mainly in cancer and palliative care, and this was probably one of the most amazing, moving and beautiful experiences I have witnessed." Gillian, Lead Nurse, Marie Curie Hospice, Newcastle "The mindfulness areas teaching me how to calm and breathe were amazing for my worry and anxiety." PID 105, FRONTLINE RELIEF: A brief evaluation "I think it's really good for taking you out of a stressful environment and calming you down. I like that there were lots of different options for what to do because people have very different preferences." University Hospital Bristol & Weston Evaluation Documentation February 2023 30|www.insightscare.com February 2023 32|www.insightscare.com Manage Pain Effective Techniques Used to How to Overcome? ain is an experience that affects people of all ages, Praces and genders. It is a universal feeling. Several things, like injuries, illnesses and long-term conditions, can bring it on. Because it can increase a patient's capacity for daily activities and improve their quality of life, pain management is an essential part of healthcare. The two most common types of pain are acute and chronic. Acute pain is typically brought on by a sudden occurrence such as surgery, bone fractures, infections, cuts and lacerations, falls, and burns. A doctor usually treats acute pain immediately following the triggering event. The pain typically subsides as the injury or condition heals, generally disappearing within six months. Let's have a look at techniques to manage pain! Medication Prescriptions are, much of the time, the primary line of treatment for torment. They fall into one of two categories: opioid and non-opioid drugs. Over-the-counter pain relievers like acetaminophen and ibuprofen and prescription medications like non-steroidal anti-inflammatory drugs (NSAIDs) are examples of non- opioid medications. Drugs like morphine, oxycodone and fentanyl are some examples of opioids. Physical Therapy Another effective method for managing pain is physical therapy. It involves stretching, exercises, and other physical methods to increase mobility and decrease pain. Patients with musculoskeletal conditions like back pain, arthritis and fibromyalgia may benefit most from physical therapy. Actual advisors can work with patients to foster individualized treatment designs that focus on the underlying driver of their aggravation. These plans may include manual therapy, therapeutic exercise, and other heat or cold therapy treatments. February 2023 33|www.insightscare.com Psychological interventions These interventions, like mindfulness meditation and cognitive-behavioral therapy (CBT), can also be helpful in pain management. Positive thought patterns that can exacerbate pain are identified and changed in CBT. Care reflection includes zeroing in on the current second and tolerating actual sensations without judgment. Patients may benefit from these methods in developing coping mechanisms that lessen the impact of pain on their daily lives. They can also improve mood and lower stress levels, which can help break the cycle of chronic pain. Chronic Pain Finding the most effective pain relief methods for one's condition can take some time due to the complexity of chronic pain. Yoga, drug treatments, and hot and cold therapy are just a few options available. An injury or a medical condition can lead to chronic pain. If pain persists for more than three months, or if it continues beyond the standard healing period for the underlying condition or injury, it is considered chronic. It can impact everything from a person's work and social life to their sleep and mental health. The Centres for Disease Control and Prevention (CDC) estimated that approximately 20% of adults in the United States had chronic pain, with 8% experiencing high-impact chronic pain. According to the Trusted Source Global Burden of Disease Study from 2017, chronic pain and related diseases are the leading causes of disability worldwide. It has a relationship with various physical and psychological well-being conditions, including wretchedness, rest issues, social segregation and abuse of prescription. Techniques to Overcome Chronic Pain Hot and cold treatment Hot and cold treatment is a typical and safe method to lessen torment. Intensity can assist with loosening up the muscles and enlarging the veins. It can also help wounds heal after an accident. Cold therapy reduces pain-causing inflammation and blood flow. The skin is frequently treated with an ice pack wrapped in a towel. Acupuncture A practitioner performs acupuncture by inserting fine needles into the skin at specific points on the body. The National Centre for Complementary and Integrative, Health Trusted Source says that there is evidence to suggest that this method could assist individuals in managing certain pain conditions. This includes temporary relief from osteoarthritis and lower back, neck and knee pain. However, there is little evidence to suggest that it is long- lastingly effective. Acupuncture has been suggested to alleviate pain, reduce inflammation, promote relaxation and lessen muscle spasms. When performed by trained practitioners with sterile needles, acupuncture is generally safe. Mind-Body Practices Yoga Yoga uses specific poses that target specific body parts to relax, strengthen and keep the body flexible. A report in 2010, into yoga's consequences for ongoing torment, found that it didn't diminish members' aggravation. Yet, it assisted them with adapting, and they were more in charge of what their aggravation meant for their day-to-day existence. On the other hand, yoga has been shown to reduce pain in other studies. It is a safe and easy way to manage pain. You can try it at home, watching videos online, or in a class with a teacher. In conclusion, Managing pain and chronic pain can be done in several ways, many of which are accessible and straightforward to use. Most pain management methods aim to lessen or enhance a person's capacity to cope with chronic pain. A professional therapist should be used for pain management techniques like acupuncture, physical therapy and yoga to ensure anyone can safely practice them. - Shreyasi Shelke February 2023 34|www.insightscare.com Soovu Labs, Inc. Relieving Pain Through an Innovative Heat Delivery Approach he old wives’ tale of taking out hot water bottles to Treduce body pain has some truth in it. And science is taking it seriously. Heat provides comfort to the body, and can reduce pain at the receptor level with the right temperature and application. Soovu Labs, Inc. has used this mechanism at its core for the discovery of new drug-free pain relief treatments. While it's difficult to use electric heating pads and hot tubs on the go and steady high temperatures can damage the skin, the company has solved these challenges with its Soovu™ Pain Relief System. Soovu™ is a wearable pain relief device with patented HeatWave™ technology that pulses waves of heat at optimal temperatures to the area that hurts, for effective, targeted pain relief. This device delivers fast and effective relief, leaving users pain-free and comforted. Following are the key benefits that set the Soovu™ device apart from other heat-delivery mechanisms. Ÿ Relief starts in as little as five minutes. Ÿ Lasting relief up to 3.5 hours. Ÿ 61% pain reduction after eight weeks. Ÿ Wireless and can be used on-the-go. In an interview with Insights Care, Allan Stephan, the CEO and Co-founder, talks in-depth about the company's innovation in treating pain drug-free. Following are the excerpts from the interview. Kindly brief us about the company and its inception story. Soovu Labs is transforming the treatment of pain by providing safe, effective alternatives to pills and invasive procedures. The company was founded by two board- certified pain specialists who grew increasingly frustrated watching many patients’ lives compromised by opioid dependence and other patients demoralized after numerous procedures failed to meaningfully reduce their pain. After securing funding from the National Institutes of Health, they teamed up with Allan Stephan, a seasoned engineer and product design executive, to develop the Soovu™ wearable thermal neuromodulation system for pain relief. Please tell us about yourself and your professional journey so far. I work on solving complex problems and have a special appreciation for the different skills and effort required to unlock puzzles. An engineer by degree, I founded my first company, Stratos, a multi-discipline product development firm, in 1987. Stratos' clientele included venture capital back companies and major organizations like Apple, Microsoft, Intel, Google, Amazon, Boston Scientific, Medtronic, and Abbott. I incubated several emerging companies in wearable computing, medical devices and life sciences within Stratos. VoxWare acquired Inroad (wearable computer) in 2000. Sony acquired Micronics (microfluidic diagnostics) in 2010. Millipore acquired Amnis (imaging flow cytometry) in 2010. Roche acquired Stratos Genomics (DNA sequencing) in 2020. In 2016, I stepped down from Stratos to lead my remaining incubation to address the world's pain epidemic, Soovu Labs. What are the core values of the company? How are you driving the company to achieve its mission and vision statement? Soovu Labs' objective is to help everyone be the best they can be. I surround myself with incredible people, clear their paths, and let them roll out solutions. Most Promising Pain Management Solu□on Providers in 2023 February 2023 36|www.insightscare.com Allan Stephan Co-founder and CEO Soovu Labs, Inc. February 2023 37|www.insightscare.com Unlike typical pain relief solutions, Soovu delivers relief within 5 minutes of the first heat therapy, is drug-free, and can be used discreetly and safely at work, home, rest or play. Quick and e□cient pain relief can improve mobility, mood, sleep and productivity as well as reduce the need for pain medication and pain therapies. Could you please list the key products and offerings of the company? Also, please put light on any service that is the company’s USP. Soovu Labs’ flagship product is the Soovu™ Pain Relief System, an FDA-registered class II medical device for the temporary relief of chronic and musculoskeletal pain and menstrual discomfort. Soovu is available without prescription and is currently marketed as a drug-free workforce pain management solution. Unlike typical pain relief solutions, Soovu delivers relief within 5 minutes of the first heat therapy, is drug-free, and can be used discreetly and safely at work, home, rest or play. Quick and efficient pain relief can improve mobility, mood, sleep and productivity as well as reduce the need for pain medication and pain therapies. In your opinion, what are the current challenges in the pain management industry? How are you infusing your leadership skills and expertise over the years to create a flourishing industry with opportunities and growth? The greatest challenge of pain is treating it without creating even more dangerous outcomes. Whether from addiction to opioids or death from heart attacks, strokes, and organ injury from NSAIDs, treating pain is a risk. My career has been looking at problems from non-traditional angles to see what others missed. We are advancing knowledge beyond existing therapies by looking at pain's pivotal role in the immune system. We see variations of our work in pain management rolling out for years to come. What are the latest technological advancements adopted by your company to deliver the best pain management services in the industry? How is it impacting the demographic concerned? The Soovu™ Pain Relief System targets the TRPV1 receptor, which was the focus of Nobel Prize-winning research in 2021 on temperature and pressure-sensitive receptors. Soovu's patented HeatWave™ thermal neuromodulation technology desensitizes the TRPV1 receptor to block the pain response for several hours. Soovu delivers relief within minutes, on par or faster than most medications, and does so without the risk of severe side effects. Its portable form factor and ability to use on the go make Soovu an ideal drug-free pain relief solution for individuals who need relief as they carry on with their lives. February 2023 38|www.insightscare.com As an experienced leader, what advice would you like to give to aspiring entrepreneurs and enthusiasts who wish to venture into the competitive industry that you are serving? If you aren't a natural salesperson, get yourself an equal partner because success is creating something people are willing to buy, and it takes longer than you'll imagine. What are the future goals of the company? How does it envision scaling up its operations and reach in 2023 and beyond? Establishing Soovu as the safest and most enjoyable method of pain reduction will always be our goal. This year, we are kicking off pilot trials with major corporations to address the enormous negative impact employees in pain have on an organization's profitability while demonstrating Soovu's positive impact on employees’ lives. Soovu will eventually address clinical pain applications and consumer solutions in years to come. Give us a few testimonials from your clients or customers, and awards or recognition that accurately highlight your company’s position in the market. “Soovu helps me get back to active life” “The first time I used my Soovu I had muscle spasms in my back, typically I need a chiropractor or massage therapy to work those out, but when I put Soovu on it helped calm the muscles down. My Soovu has become a very useful tool for when I overdo it one way or another to help me get back to active life.” - Erik L, Soovu User Entrepreneur, suffers from arthritis, avid athlete. “I bring Soovu with me and use it at work” "Soovu helps me pinpoint the area that is hurting. For me, it's instant satisfaction. I like that I can stick it on wherever I want and go on with my day, so I am not stuck on the couch. I bring the kit with me and use it at work. I let some of my co-workers borrow my pods and they swear by it, my wife loves it, it’s a great product.” - Scott S, Soovu User Building Engineer, suffers from chronic back pain from injury. “For me, relief was pretty much immediate and long- lasting” “I recently had a baby and I’ve had a lot of lower back pain since then. Since I’ve been breastfeeding, I try to minimize medications for pain and just take an occasional Tylenol, so to have Soovu as an adjunct therapy for pain has been incredibly helpful. I’ve used heat in the past to help with pain, but Soovu is different. You can feel the heat right away, in a very targeted place where you feel pain. Relief was pretty much immediate for me and long-lasting." - Sheena H, Soovu User Anesthesiologist/Pain Physician, suffers from back pain. February 2023 39|www.insightscare.com